Vancouver, Wash.-based Absci Corporation inked a research pact with Merck. Absci will leverage the company’s Bionic Protein non-standard amino acid technology and its artificial intelligence-powered integrated Drug Creation Platform to create enzymes to meet Merck’s biomanufacturing applications.
Amidst the pandemic, the biopharma industry continues to surge ahead as BioSpace reviews companies that have made recent job announcement expansions.
The BIO International Convention is being held in Philadelphia from June 3-6, 2019, with more than 16,000 attendees expected from around the world. The convention draws a list of who’s who in drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy, with more than 7,000 companies and 47,000 partnering meetings.
General Electric is diving deeper into the world of biotechnology. The conglomeration is launching prefabricated manufacturing units to product virus-based gene and cell therapies, Reuters reported.
Sanofi Genzyme, the French company’s rare-disease division based in Cambridge, Mass., announced it is laying off 130 people at a manufacturing facility in Boston.
Drug delivery company Catalent Inc. struck a deal to acquire privately held Cook Pharmica LLC, a contract manufacturing organization, for $950 million in cash.